2019
DOI: 10.1001/jamapsychiatry.2019.0779
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression

Abstract: IMPORTANCE To our knowledge, no study has previously evaluated whether individuals with bipolar depression enriched a priori on the basis of biochemical and/or phenotypic immuno-inflammatory activation would differentially respond to an anti-inflammatory agent for the treatment of depressive symptoms. OBJECTIVE To assess the antidepressant efficacy of adjunctive infliximab, a monoclonal antibody targeting tumor necrosis factor, in adults with bipolar I and bipolar II depression and inflammatory conditions. DES… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
112
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
1

Relationship

3
3

Authors

Journals

citations
Cited by 155 publications
(115 citation statements)
references
References 40 publications
3
112
0
Order By: Relevance
“…The clinical study was a 12-week randomized, double-blind, placebo-controlled, parallel-group, fixed-dose trial evaluating the efficacy, safety, and tolerability of adjunctive infliximab for the treatment of individuals with bipolar I/II depression meeting inflammatory criteria [15]. The study was approved by the Institutional Ethics Board at the University Health Network, Toronto, ON, Canada, as well as Stanford University, Palo Alto, California.…”
Section: Methodsmentioning
confidence: 99%
See 4 more Smart Citations
“…The clinical study was a 12-week randomized, double-blind, placebo-controlled, parallel-group, fixed-dose trial evaluating the efficacy, safety, and tolerability of adjunctive infliximab for the treatment of individuals with bipolar I/II depression meeting inflammatory criteria [15]. The study was approved by the Institutional Ethics Board at the University Health Network, Toronto, ON, Canada, as well as Stanford University, Palo Alto, California.…”
Section: Methodsmentioning
confidence: 99%
“…Results have been mixed. For example, whereas anti-cytokine treatments have shown antidepressant activity in chronic inflammatory conditions [13], two recent clinical trials failed to demonstrate this effect in the intent-to-treat cohorts with treatment-resistant major depressive disorder and BD [14,15].…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations